The San Diego, Calif.-based company said the deals serve to expand the reach of its drug-eluting bioresorbable scaffold, Fantom Encore.
Reva said it landed deals with the following companies: A care a.s. in the Czech Republic and Slovakia, Polimed in Poland, Technoproject in Russia and Danmeda in Lithuania, Estonia and Latvia.
Combined, these countries represent a $290 million medical device market, according to Reva, with more than 350,000 percutaneous coronary intervention procedures performed each year.
“These new distribution partnerships deliver on our commitment to expand geographic access to Fantom Encore,” CEO Reggie Groves said in prepared remarks. “These partners were selected based on their proven track records and their local knowledge of the coronary and peripheral interventions markets. We expect that they will add to the commercial momentum that we have already seen with Fantom Encore.”
Reva said it plans to kick off commercialization in each region over the next three to 12 months, contingent upon local approval.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.